« Return to News | Ethics/Regulatory

FDA names new deputy commissioner for medical products and tobacco

Friday, July 15, 2011 10:52 AM

The FDA has named former Dartmouth Medical School Dean Stephen Spielberg to the newly created position of deputy commissioner for medical products and tobacco, according to an internal letter sent to FDA employees obtained by Reuters.

The move is part of the FDA's goal to overhaul its management structure to better regulate an increasingly complex medical industry. The agency has also initiated a search to fill the newly created chief operating officer position, according to Reuters.

FDA Commissioner Margaret Hamburg promoted Deborah Autor, currently a director of the agency's compliance office, to the job of deputy commissioner for global regulatory operations and policy, according to the letter.

"The new organizational alignments more accurately reflect the agency's responsibilities, subject matter expertise and mandates in an ever more complex world, where products and services do not fit into a single category," Hamburg wrote in the letter.

Earlier this year, former Deputy Commissioner Joshua Sharfstein, who was appointed by President Barack Obama in 2009, left the agency to run the state of Maryland's health department. Under Hamburg and Sharfstein, the agency had become more aggressive in its oversight of companies for product-safety problems, shoddy manufacturing and misleading advertisements.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.